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Metabolic profiling and targeted 
lipidomics reveals a disturbed lipid 
profile in mothers and fetuses with 
intrauterine growth restriction
Jezid Miranda1, Rui V. Simões1, Cristina Paules1, Daniel Cañueto  2, Miguel A. Pardo-Cea3, 
María L. García-Martín  4, Francesca Crovetto1, Rocio Fuertes-Martin  2,3, Monica Domenech5, 
María D. Gómez-Roig1, Elisenda Eixarch1, Ramon Estruch5,6, Stefan R. Hansson7, Nuria Amigó3, 
Nicolau Cañellas2,8, Fatima Crispi1 & Eduard Gratacós1
Fetal growth may be impaired by poor placental function or maternal conditions, each of which 
can influence the transfer of nutrients and oxygen from the mother to the developing fetus. 
Large-scale studies of metabolites (metabolomics) are key to understand cellular metabolism and 
pathophysiology of human conditions. Herein, maternal and cord blood plasma samples were 
used for NMR-based metabolic fingerprinting and profiling, including analysis of the enrichment of 
circulating lipid classes and subclasses, as well as the number of sub-fraction particles and their size. 
Changes in phosphatidylcholines and glycoproteins were prominent in growth-restricted fetuses 
indicating significant alterations in their abundance and biophysical properties. Lipoprotein profiles 
showed significantly lower plasma concentrations of cholesterol-intermediate density lipoprotein 
(IDL), triglycerides-IDL and high-density lipoprotein (HDL) in mothers of growth-restricted fetuses 
compared to controls (p < 0.05). In contrast, growth-restricted fetuses had significantly higher 
plasma concentrations of cholesterol and triglycerides transporting lipoproteins [LDL, IDL, and VLDL, 
(p < 0.005; all)], as well as increased VLDL particle types (large, medium and small). Significant changes 
in plasma concentrations of formate, histidine, isoleucine and citrate in growth-restricted fetuses were 
also observed. Comprehensive metabolic profiling reveals that both, mother and fetuses of pregnancies 
complicated with fetal growth restriction have a substantial disruption in lipid metabolism.
Fetal growth restriction (FGR) affects 6–10% of all pregnancies and is defined as the failure to achieve the genetic 
growth potential, resulting in a given low birthweight1. Growth restricted fetuses have a 5 to 10-fold risk of dying 
in utero, and higher risk of perinatal morbidity and mortality2,3. In addition, fetuses with growth restriction 
show metabolic and cardiovascular adaptations that are thought to persist postnatally, with implications for adult 
disease and repercussions for preventive strategies. A small fraction of the small fetuses diagnosed in utero pres-
ent as early-onset/severe fetal growth restriction4. However, the majority of clinical instances of fetal smallness 
occur late in gestation under two main phenotypes, conventionally defined as small for gestational age (SGA) 
and FGR5,6. While the former is usually associated with near-normal perinatal outcomes and are considered 
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“constitutionally small fetuses”, FGR is characterized by placental maldevelopment and abnormal fetoplacental 
blood flow7, a higher risk of fetal death3,8–10 and poor perinatal outcomes11,12. It is unclear whether SGA and 
FGR are different conditions or represent different degrees of severity of the same disease. For instance, despite 
the clear differences in obstetrical risks, both SGA and FGR show similar features of long-term fetal adaptation 
to intrauterine undernutrition, including signs of cardiac remodeling13–17, differences in brain cortical develop-
ment18–20 and microstructure21–23, as well as a higher prevalence of neurodevelopmental delay24–27.
The metabolome of biological fluids represents a sensitive and multifactorial phenotypic signature of dis-
ease, providing insights of the interface between the final downstream products of gene expression, the influence 
of environmental factors and the complex interactions between them28–31. In addition, recent sensitive, rapid, 
and high-throughput technology advances have provided a solution to measure low concentrated metabolites 
in human plasma, allowing a comprehensive profiling of metabolic changes in-vivo32–34. Fetal growth may be 
impaired by poor placental function or maternal conditions, each of which can influence the transfer of nutrients 
and oxygen from the mother to the developing fetus35. We and others have previously explored the metabolomic 
profile of fetuses with impaired intrauterine growth36–39. Specifically, a metabolomic analysis of cord blood from 
early and late-onset FGR revealed significant differences in essentials amino acids as well as an abnormal lipid 
metabolism in both, early and late-onset FGR; particularly at the expense of unsaturated lipids38. However, the 
enrichment of circulating lipid classes and subclasses, as well as the number of sub-fraction particles and their 
size, has not been analyzed in detail. Furthermore, the co-existence of metabolic changes in the maternal com-
partment has not been explored. A simultaneous and comprehensive characterization of the metabolomic profile 
of mothers and fetuses with suboptimal fetal growth could provide further insights into the pathophysiological 
changes underlying these clinical forms of fetal smallness. The objective of this study was to analyze the maternal 
and cord blood plasma metabolome in pregnancies with two clinical phenotypes of late-onset fetal smallness, 
SGA and FGR, and to compare them with those from pregnancies with a normal fetal growth.
Results
Clinical characteristics of participants. From October 2014 to March 2016, 80 pregnant women were 
recruited. Among those, 28 had a normal sonographic estimation of fetal weight that was confirmed at birth 
[Adequate-for-gestational age fetuses (AGA)] and 52 pregnancies had an antenatal diagnosis of fetal smallness 
[estimated sonographic fetal weight (EFW) below the 10th centile] that was confirmed at birth (birthweight <10th 
centile) and were included as cases. According to our clinical protocol, small fetuses were subdivided as follows: 
those with an EFW <3rd centile (confirmed at birth) and/or abnormal uteroplacental flow defined by an abnormal 
uterine artery Doppler velocimetry and/or abnormal cerebroplacental ratio (a sonographic Doppler parameter 
that indicates redistribution of fetal cerebral blood flow) were termed fetal growth restriction (FGR; n = 27), while 
those with a birthweight between the 3rd and the 9th centile and normal fetoplacental Doppler were considered 
small-for-gestational age (SGA; n = 25) cases5,40,41.
The maternal sociodemographic and obstetric characteristics are summarized in Table 1. There were no sig-
nificant differences in maternal age, race, smoking or rate of maternal underweight [pre-gestational body mass 
index (BMI) <18 kg/m2] or obesity (BMI >30 kg/m2) among the study groups (all p values > 0.05). Furthermore, 
there were no significant differences between SGA and FGR (p = 0.07) or AGA (p = 0.21) when we analyze 
pre-gestational BMI as a continuous variable (Table 1).
According to the design of the study, there were no significant differences in the gestational age at recruitment, 
cases had a significantly lower estimated sonographic fetal weight compared to controls and all patients delivered 
at term (>37 weeks of gestation). FGR cases had significantly higher rate of abnormal uterine artery Doppler and 
worse fetoplacental Doppler parameters as compared to controls and SGA. There were no significant differences 
in the gestational age at delivery between SGA cases and controls (p = 0.15); however, it was significantly lower in 
FGR cases (p = 0.002). The rate of induction of labor was significantly higher in cases; nevertheless, there were no 
differences in the route of delivery or rate of preeclampsia among the study groups (Table 1).
1H-NMR spectral fingerprinting in maternal and cord blood spectra. The average Diff spectral 
vectors generated for maternal and cord blood plasma are shown in Fig. 1. There were differences observed 
in the spectral vectors among the groups, more evident at 1.29 and 0.89 ppm, suggesting lower relative plasma 
concentrations of lipids in mothers of small fetuses (both, in SGA and FGR cases), while in cord blood, the rel-
ative concentrations of lipids were higher in cases, and mostly in the FGR group. To evaluate the ability of these 
metabolites in distinguishing small fetuses from controls, we performed non-targeted multivariate discriminant 
analysis. Fig. 2 represents the loading weight of each spectral point extracted from an OPLS-DA model of the data 
set (i.e. the most influential regions of the spectrum that are responsible for discrimination between cases and 
controls). The most discriminatory regions corresponded to lipids, CH2 and CH3, in both, mothers and fetuses 
[(CH2)n, 1.29 ppm and CH3 at 0.89 ppm)], confirming that these lipids: decrease in mothers of fetuses with FGR 
and SGA compared to controls, and increase in small fetuses. Furthermore, the approach yielded new findings 
such as an increase in choline compounds (in this case, most likely phosphatidylcholine) in fetuses (Fig. 2).
Metabolic fingerprinting in clinical phenotypes of small fetuses. Based on the non-targeted metab-
olomics results obtained, quantitative targeted analyses using Liposcale (for lipid profiling, deconvolution of 
phosphatidylcholines and glycoproteins) and Dolphin (for LMW metabolite profiling) were performed (Fig. S1). 
The lipoproteins identified and their concentrations (i.e. triglycerides and cholesterol), strongly correlated to the 
enzymatic colorimetric methods quantifications for the same subjects (Fig. S2). Tables 2 and 3, shows the lipo-
proteins identified and their concentrations, phosphatidylcholines and glycoprotein properties, as well as LMW 
metabolites for each clinical phenotype (SGA and FGR) in maternal and cord blood, respectively. The Liposcale 
analysis showed that mothers of SGA fetuses had significantly lower concentrations of cholesterol-IDL compared 
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to controls (p = 0.02). Similarly, triglycerides transporting lipoproteins, IDL and HDL, were significantly lower 
in mothers of fetuses with sub-optimal fetal growth compared to AGA mothers (p = 0.01, 0.03 and 0.02, respec-
tively) (Table 2). In terms of lipoproteins properties, there were lower concentrations of large HDL lipoproteins in 
mothers of FGR fetuses (p = 0.04). Changes in glycoproteins and phosphatidylcholines suggested a disruption in 
their biophysical properties among study groups. Specifically, the width of one of the phosphatidylcholines peaks 
was significantly lower in FGR cases (p = 0.02). With regards to LMW metabolites, maternal plasma concentra-
tions of alanine, citrate, 2-oxoisovaleric acid and pyruvate were significantly lower in mothers of small fetuses 
compared to controls (all p values < 0.05) (Table 2).
Interestingly, the behavior of triglycerides and cholesterol lipoproteins was the opposite in affected fetuses com-
pared to their mothers. FGR fetuses had significantly higher concentrations of cholesterol-VLDL (+56%), -IDL 
(+24%) lipoproteins (p = 0.008 and 0.04, respectively), as well as higher concentrations of triglycerides-VLDL 
(+24%), and -IDL (+18%) compared to controls (p = 0.008 and 0.04, respectively) (Table 3). Importantly, we 
found a gradient of higher concentrations of cholesterol (VLDL and IDL) and triglycerides (VLDL, IDL and LDL) 
lipoproteins in SGA and FGR cases compared to controls (Jonckheere–Terpstra test p < 0.05). FGR cases also 
showed a significant increase in large HDL, medium LDL and all VLDL particle types (large, medium and small: 
average + 37%) vs. controls (all p values < 0.05). When analyzed as a trend, the Jonckheere-Terpstra test also 
showed that the increase in particles size and distribution was present in the two clinical phenotypes following a 
severity ascendant gradient, higher in FGR fetuses. Likewise, changes in phosphatidylcholines and glycoproteins 
Adequate for Gestational 
Age N = 28
Small for Gestational 
Age N = 25
Fetal Growth 
Restriction N = 27 p value
n (%) or median (IQR) n (%) or median (IQR) n (%) or median (IQR) K-wallis
Maternal baseline characteristics
Maternal age (years) 32 (30.5–36.5) 30 (25–35) 31.5 (28–34) 0.16
Maternal race 0.77
   White 23 (82.1) 19 (79.2) 24 (92.3)
   Latin 2 (7.1) 3 (12.5) 1 (3.8)
   Indian/Pakistan 2 (7.1) 1 (4.2) 1 (3.8)
   Others 1 (3.6) 1 (4.2) 0
Pre-gestational maternal BMI (kg/m2) 0.21
    < 18.5 1 (3.57) 1 (4.3) 5 (20)
   18.5–25 19 (67.9) 17 (74) 16 (64)
   25–30 5 (17.9) 5 (21.7) 4 (16)
    > 30 3 (10.7) 0 0
   Smoking 4 (14.2) 8 (32) 5 (18.5) 0.3
Ultrasound parameters at third trimester evaluation
GA at recruitment (weeks) 32.3 (30–34.8) 33.8 (31.3–36.4) 34.4 (32–36) 0.19
Estimated fetal weight (grams) 2131 (1477–2615) 1866 (1406–2134) 1788 (1567–2040) 0.24
Estimated fetal weight centile 50 (39–77) 5 (3–9) 3 (1–6) 0.0001
Mean uterine artery PI (Z-score) −0.4 (−1.1–0.67) 0.2 (−0.14–0.78) 1.05 (−0.86–2.02) 0.15
Mean uterine artery PI > 95th centile 1 (4.2) 0 9 (36) 0.001
Umbilical artery PI (Z-score) −0.26 (−0.58–0.29) −0.1 (−0.68–0.4) 0.44 (−0.1–0.65)* 0.02
Umbilical artery PI > 95th centile 0 0 3 (11.1) 0.1
Cerebroplacental ratio (Z-score) −0.16 (−0.7–0.47) −0.51 (−1.43–0.16) −1.08 (−1.45–0.11)*¥ 0.16
Cerebroplacental ratio < p5th centile 3 (12) 0 5 (18.5) 0.74
Perinatal outcomes
GA at delivery (weeks) 39.8 (39–40.5) 39.4 (38.1–40.3) 37.8 (37.3–39.6)*¥ 0.002
Birthweight (grams) 3365(3060–3575) 2728
¥ (2500–2860)¥ 2245 (2100–2506)*¥ 0.0001
Birthweight centile 42 (35.5–68.5) 6 (4–9)¥ 1 (0–2)*¥ 0.0001
Male gender 11 (39.3) 11 (44) 19 (70.4) 0.05
Induction of labor 6 (21.4) 13 (52) 18 (66.7) 0.003
Route of delivery 0.67
Vaginal delivery 18 (64.3) 11 (44) 15 (55.6)
Cesarean section 9 (32.1) 12 (48) 10 (37)
Operative vaginal delivery 1 (3.6) 2 (8) 2 (7.4)
Preeclampsia 0 0 3 (11.1) 0.9
Table 1. Clinical characteristics of the study groups. BMI: Body mass index; GA: Gestational age; PI: Pulsatility 
index; Missing values: Race (2); BMI (4); Uterine artery Doppler velocimetry (6); Umbilical artery Doppler 
velocimetry (4) and cerebroplacental ratio (4). *Statistically significant different (p < 0.05), between SGA and 
FGR. ¥Statistically significant different as compared to AGA.
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peaks were more prominent in FGR fetuses vs. controls (Table 3). Conversely, among LMW metabolites, formate 
and acetate showed a significant trend towards increase in cord blood of FGR fetuses (p = 0.02 and 0.01, respec-
tively) (Table 3). No differences were found in the concentrations of glucose between the study groups. Figure. 3 
is a heat map constructed to visualize and summarize the significant differences on the maternal and cord blood 
plasma LMW metabolites, lipid classes, particles and subclasses along with their p-values, and percentage of fold 
change (among cases and controls).
Figure 1. Maternal and cord blood nuclear magnetic resonance profiles among the study groups. The more 
evident differences in the Diff spectral vectors were observed at 1.29 and 0.89 ppm, suggesting lower relative 
plasma concentrations of lipids in mothers of small fetuses (both, in SGA and FGR cases), while in cord blood, 
the relative concentrations of lipids were higher in cases, being greater in FGR compared to SGA cases, as well 
as compared to controls.
Figure 2. Loading weight of each spectral variable extracted from an orthogonal partial least square 
discriminant analysis model (ASCLAN) of the data set among the study population. The color-coded loading 
plot shows the discriminatory variables, non-discriminatory signal variables and the noise variables, which are 
indicated by red, blue and grey, respectively. The loading plot shows the most influential regions of the spectrum 
that are responsible for discrimination between cases and controls.
www.nature.com/scientificreports/




Small for Gestational 
Age N = 25
Fetal Growth 
Restriction N = 27 p values





VLDL 40.5 (30.7–68) 30.2 (23.9–49.7) 33.7 (24.3–49.8) 0.06 0.09 0.04
IDL 35.4 (26.2–46.3) 30.9 (24.1–34.3) 30 (19.2–37.4) 0.02 0.06 0.01
LDL 175 (150–217) 186.7 (170.2–197) 182.5 (148.6–201.5) 0.97 0.63 0.66
HDL 78.9 (65.9–96.9) 80.9 (71–98.6) 86.5 (77.8–94.1) 0.75 0.24 0.89
Triglycerides (mg/dL)
VLDL 137.8 (109.8–228) 116.9 (87.6–163.9) 117.9 (92.5–170.2) 0.17 0.14 0.08
IDL 30 (25.1–35.8) 26.1 (21.5–29.6) 27.4 (20–32.5) 0.01 0.09 0.02
LDL 42.7 (36.1–52.1) 38.8 (32.2–42.8) 39.2 (27.9–44.3) 0.07 0.12 0.04




Large 3.2 (2.5–4.8) 3.1 (2.3–4.1) 2.9 (2.1–4.1) 0.3 0.14 0.08
Medium 14.4 (11.3–21) 12 (8.5–16.7) 12.9 (10–16.5) 0.15 0.21 0.11
Small 83.1 (65.2–146) 66.4 (50–99) 68 (52.9–104) 0.14 0.08 0.05
LDL
Large 201 (163–249) 203 (170–223) 201 (152–217) 0.52 0.28 0.11
Medium 520 (468–651) 527 (486–583) 526 (411–596) 0.98 0.44 0.28
Small 621 (490–745) 591 (514–746.7) 632 (471–708) 0.90 0.61 0.30
HDL
Large 0.72 (0.16–1.52) 0.24 (0.06–0.91) 0.37 (0.04–0.88) 0.08 0.04 0.02
Medium 13.1 (10–17.7) 14 (12.9–17.1) 14.8 (13.2–16.7) 0.59 0.04 0.84
Small 34.3 (30.1–39.8) 33.9 (28.4–38.7) 35.7 (32–38.4) 0.72 0.49 0.30
Phosphatidylcholines
Area peak 1 2 (1.6–2.7) × 106 1.8 (1.6–2.2) × 106 1.9 (1.2–2.4) × 106 0.19 0.16 0.91
Height peak 1 77 (62–101) × 103 71 (67–79) × 103 76 (51.7–91.7) × 103 0.27 0.19 0.13
Width peak 1 8.71 (8.3–9.1) 8.32 (7.7–9.2) 8.13 (7.7–8.8) 0.12 0.02 0.01
Area peak 2 0.21 (0.1–0.3) × 106 0.36 (0.14–0.5) × 106 0.29 (0.1–0.4) × 106 0.56 0.68 0.56
Height peak 2 21 (9.5–28.4) × 103 25 (14–35) × 103 22 (10.7–31.4) × 103 0.70 0.90 0.47
Width peak 2 3.8 (3.2–4.3) 4.6 (3.3–4.9) 4.1 (3.5–4.6) 0.11 0.37 0.83
Area peak 3 3.4 (2.3–4.1) × 106 2.7 (1.7–4.2) × 106 3 (2–4.1) × 106 0.42 0.89 0.44
Height peak 3 164 (105–226) × 103 136 (80–198) × 103 149 (97–220) × 103 0.38 0.83 0.41
Width peak 3 6.7 (6.4–7.2) 6.9 (6.5–7.2) 6.8 (6.5–7.2) 0.55 0.8 0.61
Area peak 4 3.3 (2.8–3.9) × 106 3.5 (2.7–4) × 106 3.3 (3.1–3.9) × 106 0.72 0.69 0.59
Height peak 4 120 (103–151) × 103 124 (108–144) × 103 123 (111–137) × 103 0.88 0.99 0.48
Width peak 4 8.8 (8.4–9.2) 9.1 (8.5–9.6) 8.8 (8.3–9.4) 0.11 0.63 0.74
Glycoproteins
Area peak 1 0.47 (0.37–0.54) × 106 0.49 (0.35–0.59) × 106 0.5 (0.39–0.63) × 106 0.83 0.18 0.89
Height peak 1 23.4 (20–25.1) × 103 23 (17–25.6) × 103 23.5 (21–26.8) × 103 0.76 0.51 0.71
Width peak 1 6.8 (5.7–7.2) 6.80 (5.68–7.64) 7.16 (6.5–8.2) 0.48 0.07 0.04
Area peak 2 2.8 (2.2–3.7) × 106 2.4 (1.9–3.76) × 106 2.7 (2.2–3) × 106 0.39 0.44 0.27
Height peak 2 124 (104–157) × 103 110 (94–155) × 103 123 (111–135) × 103 0.38 0.48 0.70
Width peak 2 7.37 (6.4–8.2) 6.88 (6.5–8.5) 7.28 (6.35–7.9) 0.8 0.4 0.28
Area peak 3 30 (27–31.6) × 106 25.6 (23.2–30.6) × 106 26.7 (23.5–30.4) × 106 0.09 0.08 0.03
Height peak 3 280 (256–357) × 103 261 (221–341) × 103 248 (219–327) × 103 0.07 0.13 0.04
Width peak 3 35 (31–37.6) 36.3 (32.9–38.8) 34.3 (32.9–36.8) 0.24 0.53 0.66
Low molecular weight metabolites (mM)
Acetate 0.05 (0.04–0.08) 0.06 (0.05–0.12) 0.07 (0.05–0.09) 0.07 0.19 0.07
Acetone 0.22 (0.13–0.31) 0.19 (0.13–0.25) 0.21 (0.11–0.27) 0.67 0.29 0.16
Alanine 1.17 (1.02–1.34) 1.15 (0.99–1.34) 1.02 (0.89–1.19) 0.55 0.04 0.02
Citrate 0.69 (0.64–0.74) 0.64 (0.56–0.69) 0.56 (0.50–0.68) 0.04 0.01 0.002
Creatine 0.13 (0.11–0.15) 0.12 (0.09–0.16) 0.13 (0.10–0.16) 0.95 0.63 0.67
Creatinine 0.20 (0.18–0.22) 0.2 (0.17–0.22) 0.19 (0.16–0.21) 0.73 0.35 0.17
Formate 0.09 (0.07–0.11) 0.1 (0.09–0.12) 0.09 (0.08–0.13) 0.17 0.48 0.78
Glucose 5.58 (4.90–6.19) 5.8 (4.13–6.89) 5.35 (4.93–6.39) 0.83 0.93 0.54
Glutamine 1.1 (0.9–1.2) 1.09 (0.80–1.27) 1.06 (1.0–1.33) 0.95 0.51 0.76
Glycine 0.59 (0.48–0.66) 0.58 (0.51–0.66) 0.64 (0.51–0.73) 0.64 0.39 0.78
Continued
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Discussion
Principal findings of the study. In this comprehensive metabolomic study, we expanded previous obser-
vations that lipid profiles are disturbed in small fetuses and their mothers. Yet, our innovative approach allowed 
quantifying the number and size of the particles in the lipoprotein fractions as well as low-molecular-weight 
metabolites, describing the complex maternal and fetal metabolic response in pregnancies with fetal smallness. 
However, the study failed to observe any remarkable difference between the two clinical phenotypes of fetal 
smallness. Thus, SGA and FGR presented similar findings, supporting the notion that both phenotypes might be 
exposed to different degrees of undernutrition and thus, both might be at risk of metabolic fetal programming. 
Future studies assessing placenta metabolism might delineate potential mechanisms in both phenotypes.
Why are circulating lipids lower in mothers of growth-restricted fetuses?. Our results describing 
an overall decrease in circulating lipids in mothers of small fetuses are in line with previous studies42–47. However, 
this study revealed further details, providing qualitative and quantitative measurements of lipoproteins, their cho-
lesterol and triglyceride concentration, as well as the number of sub-fraction particles and their size. Compared to 
controls, there was a triglyceride-impoverishment in lipoproteins such as HDL (decrease in large particles) and 
IDL as well as low concentration of cholesterol in other lipoproteins, namely VLDL and IDL in mothers of both 
SGA and FGR cases. A maternal metabolic adaptation during pregnancy47–53 is essential to increase availability 
of cholesterol and triglycerides for fetal development and the synthesis of steroid hormones by the placenta54–56. 
When maternal plasma cholesterol is low, birthweight is lower than normal. Indeed, term infants of mothers 
with low total cholesterol weigh are on average 150 g less than those born to mothers with normal cholesterol 
concentrations57. The first trimester of gestation is considered an anabolic period, in which the mother increases 
her deposit of fat, through a reduction in the activity of lipoprotein lipase, and increasing in the insulin responsive-
ness58. Interestingly, this fat accumulation is maintained even under conditions of severe maternal malnutrition59. 
In the third trimester, a switch to catabolism occurs in order to supply fetal demands and to synthesize large 
amounts of steroids hormones by the placenta54. The products of an enhanced lipolytic activity reach the liver to 
be used for triglycerides synthesis and to increase circulating availability of triglycerides by 208% (transported 
mainly by VLDL), and total, HDL- and LDL-cholesterol in 65, 26 and 64%, respectively50. It seems plausible that 
in the third trimester of pregnancy, placental insufficiency generates a specific fetal and maternal response that 
is reflected in the metabolomic profile. Low concentrations of lipids in the maternal circulation may reflect an 
increased uptake into the placenta. In normal gestation, support of lipids, and particularly essential fatty acids, to 
the fetus is ensured by increased maternal liver production of VLDL rich in triglycerides (build upon peripheral 
deposits of adipose tissue)60, peripheral enrichment of HDL and LDL and lipoprotein lipase activities in the pla-
centa61,62. The findings of this and previous studies suggest (1) failure of the normal signaling leading to increased 
lipids in pregnancy, and/or (2) a reduction in lipid reserve in the mothers.
Why are there higher cord blood lipids in SGA and FGR fetuses?. Our findings confirmed previous 
studies reporting higher circulating triglycerides and cholesterol lipoproteins in growth-restricted fetuses63–66. 
Importantly, our metabolic fingerprinting approach allowed to describe that VLDL and IDL were the most dereg-
ulated lipoproteins in FGR fetuses, suggesting that VLDL rich in triglycerides may be an alternative fuel mobi-
lized by the growth-restricted fetus. This is a novel finding in humans, since VLDL is mostly synthesized in the 
fetal liver, implying an altered hepatic synthesis of lipoproteins in adverse intrauterine conditions.
Lipids are fundamental molecules for life. During fetal life, triacylglycerols provide energy for metabolic pro-
cesses, while fatty acids, cholesterol and phospholipids are required to develop the fetal brain and central nervous 
system, to build cell membranes, and as a precursor of bile acids and steroid hormones67. Both, the placenta and 




Small for Gestational 
Age N = 25
Fetal Growth 
Restriction N = 27 p values
Median (IQR) Median (IQR) Median (IQR) AGA vs. SGA AGA vs. FGR
Jonckheere-
Terpstra test
Histidine 0.24 (0.20–0.28) 0.20 (0.17–0.27) 0.22 (0.19–0.24) 0.33 0.17 0.11
Isoleucine 0.17 (0.15–0.2) 0.15 (0.12–0.2) 0.16 (0.13–0.2) 0.14 0.5 0.26
Lactate 11 (7.57–14) 11.67 (7.14–15.2) 11 (7.16–13.5) 0.98 0.61 0.32
Leucine 0.22 (0.2–0.26) 0.21 (0.16–0.25) 0.24 (0.18–0.28) 0.26 0.83 0.56
Mannose 0.21 (0.19–0.23) 0.2 (0.16–0.23) 0.19 (0.17–0.2) 0.16 0.13 0.06
2-oxoisovaleric acid 1.02 (0.84–1.27) 0.77 (0.66–0.94) 0.78 (0.69–0.94) 0.0009 0.002 0.001
Phenylalanine 0.28 (0.26–0.3) 0.3 (0.26–0.32) 0.3 (0.27–0.35) 0.22 0.1 0.04
Pyruvate 0.65 (0.43–0.75) 0.5 (0.34–0.73) 0.44 (0.35–0.56) 0.18 0.05 0.03
Tyrosine 0.32 (0.28–0.37) 0.32 (0.28–0.37) 0.32 (0.27–0.37) 0.8 0.90 0.43
Valine 0.52 (0.45–0.57) 0.51 (0.42–0.59) 0.52 (0.46–0.57) 0.58 0.81 0.57
Table 2. Metabolic profiling and targeted metabolomics in maternal blood across the study groups. HDL: 
High-density lipoprotein; IDL: Intermediate density lipoprotein; IQR: Interquartile range; LDL: Low-density 
lipoprotein; VLDL: Very low-density lipoprotein. Concentration, size and properties of the peaks are presented 
as median and interquartile range (IQR).
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Adequate for Gestational 
Age N = 28
Small for Gestational 
Age N = 25
Fetal Growth 
Restriction N = 27 p values









VLDL 8.6 (7.47–11.1) 10.8 (8.4–13.7) 13.5 (9.2–17.2) 0.1 0.008 0.002
IDL 7.1 (6.4–8.9) 8.6 (7.2–10.5) 8.8 (8–10.8) 0.08 0.04 0.01
LDL 82.1 (79–86) 80.7 (78.9–86.5) 80.5 (78.3–86.9) 0.98 0.73 0.63
HDL 61.9 (58.9–65.1) 61.6 (58.7–64.2) 56.5 (53.5–63.3) 0.81 0.06 0.97
Triglycerides (mg/dL)
VLDL 39.6 (35.7–45.4) 45.3 (37.8–52.3) 50.4 (42.2–61.7) 0.1 0.007 0.002
IDL 7.8 (7.1–9.4) 8.9 (7.9–10.5) 9.3 (8.6–11.1) 0.08 0.03 0.008
LDL 6.7 (5.8–8.5) 8.1 (6.2–9.3) 7.3 (6.7–9.7) 0.2 0.09 0.04





Large 0.9 (0.75–1.1) 1.1 (0.79–1.32) 1.23 (1–1.6) 0.15 0.004 0.001
Medium 4.8 (4.5–5.6) 5.57 (4.7–5.9) 6 (5–6.8) 0.11 0.003 0.001
Small 19.6 (16.5–24.3) 20.6 (17.1–30.6) 27.5 (19.4–34.3) 0.22 0.03 0.01
LDL
Large 82.9 (74–88.7) 83.7 (78.4–91) 83.5 (73–90.6) 0.76 0.86 0.56
Medium 188 (180–202) 201 (181–209) 202 (192–213) 0.13 0.04 0.02
Small 294 (270–315) 286 (267–329) 292 (257–317) 0.55 0.67 0.74
HDL
Large 0.23 (0.14–0.31) 0.23 (0.18–0.35) 0.34 (0.26–0.5) 0.7 0.009 0.003
Medium 10.4 (9.6–11.7) 10.8 (10.2–11.8) 9.7 (7.4–11.7) 0.48 0.06 0.1
Small 19.6 (17.9–20.8) 18.9 (17.6–22) 18.9 (17.7–21.1) 0.78 0.59 0.72
Phosphatidylcholines
Area peak 1 0.4 (0.32–0.44) × 106 0.42 (0.32–0.54) × 106 0.51 (0.4–0.58) × 106 0.32 0.04 0.01
Height peak 1 14.5 (13.2–16.5) × 103 16.5 (13–19) × 103 17.6 (15.5–21.4) × 103 0.18 0.006 0.003
Width peak 1 8.9 (8.1–9.6) 8.6 (8.3–9.2) 8.5 (8.2–9.4) 0.34 0.37 0.86
Area peak 2 0.34 (0.2–0.41) × 106 0.41 (0.21–0.5) × 106 0.26 (0.15–0.48) × 106 0.22 0.42 0.72
Height peak 2 17 (13.6–20.4) × 103 20 (14.4–26) × 103 16 (10–24.2) × 103 0.09 0.88 0.36
Width peak 2 6.37 (4.6–7.3) 6.5 (5.4–6.9) 5.7 (4.5–7.1) 0.98 0.19 0.94
Area peak 3 0.79 (0.34–1.18) × 106 1.19 (0.53–1.83) × 106 0.66 (0.22–1.56) × 106 0.31 0.78 0.57
Height peak 3 35.1 (21.4–53.2) × 103 55.2 (27.4–78.4) × 103 31.7 (12.6–59) × 103 0.21 0.76 0.58
Width peak 3 7 (5.8–8.1) 7.1 (5.3–7.9) 7.4 (5.8–9.2) 0.62 0.59 0.26
Area peak 4 2.1 (1.85–2.41) × 106 1.76 (1.1–2.42) × 106 1.76 (1.3–2.29) × 106 0.12 0.05 0.03
Height peak 4 76 (65.2–87.8) × 103 62.3 (46.3–82.3) × 103 64.7 (49.1–81) × 103 0.08 0.07 0.05
Width peak 4 9.3 (8.74–9.6) 9.1 (8.5–9.5) 8.9 (8.4–9.2) 0.26 0.07 0.04
Glycoproteins
Area peak 1 0.44 (0.36–0.56) × 106 0.43 (0.36–0.56) × 106 0.46 (0.37–0.56) × 106 0.96 0.71 0.37
Height peak 1 13 (11.8–14.4) × 103 12.7 (11.4–14.3) × 103 13.9 (11.8–16.1) × 103 0.53 0.21 0.14
Width peak 1 11.3 (10.2–12.6) 10.9 (10–12) 11 (10.1–12.1) 0.43 0.5 0.72
Area peak 2 1.3 (1.2–1.4) × 106 1.4 (1.3–1.69) × 106 1.6 (1.4–2) × 106 0.08 0.002 0.0004
Height peak 2 52.4 (48–56.2) × 103 53 (50–66) × 103 59.9 (53.5–70.2) × 103 0.17 0.009 0.003
Width peak 2 8.3 (7.9–8.5) 8.4 (8.1–8.6) 8.6 (8.4–9.2) 0.24 0.005 0.002
Area peak 3 7.2 (5.6–8.4) × 106 7.3 (6.3–8.9) × 106 6.7 (5.5–7.7) × 106 0.59 0.64 0.68
Height peak 3 55 (44–64) × 103 61.2 (48–71) × 103 59 (51.4–70.4) × 103 0.15 0.19 0.1
Width peak 3 46.6 (38–50) 43.7 (37–49.8) 38 (33.2–43.9) 0.18 0.002 0.0005
Low molecular weight metabolites (mM)
Acetate 0.06 (0.05–0.08) 0.07 (0.06–0.09) 0.08 (0.07–0.10) 0.07 0.01 0.003
Acetone 0.12 (0.09–0.23) 0.12 (0.08–0.21) 0.1 (0.07–0.17) 0.69 0.24 0.87
Alanine 1.7 (1.41–1.9) 1.6 (1.4–1.9) 1.7 (1.4–1.9) 0.66 0.90 0.47
Citrate 0.53 (0.5–0.6) 0.6 (0.5–0.6) 0.6 (0.4–0.61) 0.96 0.6 0.67
Creatine 0.16 (0.12–0.2) 0.17 (0.13–0.2) 0.18 (0.15–0.25) 0.72 0.25 0.12
Creatinine 0.17 (0.16–0.2) 0.18 (0.17–0.2) 0.18 (0.14–0.22) 0.34 0.78 0.33
Formate 0.12 (0.1–0.15) 0.16 (0.12–0.17) 0.16 (0.11–0.19) 0.02 0.02 0.004
Glucose 4.25 (3.88–5.1) 4.42 (3.7–5.03) 4.6 (3.9–5.38) 0.84 0.33 0.2
Glutamine 1.35 (1.2–1.5) 1.39 (1.29–1.6) 1.42 (1.24–1.56) 0.42 0.53 0.26
Glycine 1.1 (0.96–1.22) 1.1 (0.94–1.1) 1.1 (0.97–1.22) 0.64 0.63 0.3
Histidine 0.42 (0.39–0.45) 0.39 (0.34–0.44) 0.39 (0.35–0.46) 0.22 0.2 0.09
Continued
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could derive from transplacental passage. Maternal cholesterol-carrying lipoproteins (mainly HDL) are trans-
ported across trophoblast and then overpass the endothelial cells of the fetoplacental vasculature, to finally 
being effluxed into the fetal circulation60. Thus, like in the adult, the liver is the principal source of circulating 
lipoproteins in the fetus. Previous animal68 and human studies have shown higher concentrations of circulating 
triglycerides64,69,70, as well as an altered, pro-atherogenic lipid and cholesterol metabolism in growth-restricted 
fetuses38,71,72. The lipid profile of FGR fetuses described herein is akin to adults with dyslipidemia and atheroscle-
rosis. Large epidemiological as well as experimental evidence have suggested that an adverse intrauterine envi-
ronment leading to low birthweight may increase the risk for cardiovascular disease later in life73–77. Therefore, 
important challenges for future research are to ascertain the mechanistic pathways whereby fetal abnormal lipid 
profile might influence the higher risk of growth restricted fetuses to cardiovascular disease in adulthood.
Changes in low molecular weight metabolites. While major changes were found in lipids, analysis of 
LMW metabolites revealed lower cord blood concentrations of acetate and formate in late-onset FGR and mater-
nal concentrations of citrate, pyruvate and 2-oxoisovaleric acid in both, SGA and FGR pregnancies. Biophysical 
abnormalities in phosphatidylcholines and glycoproteins were also detected. Phosphatidylcholine is a major 
membrane phospholipid, made in mammalian cells from choline via the CDP-choline pathway and has a key 
role in neuronal differentiation and cell fate determination78. Importantly, phosphatidylcholine biosynthesis 
is required for normal VLDL secretion from hepatocytes79. Metabolomic analysis showed some differences in 
comparison with previous studies. For instance, in this study we did not replicate our previous finding of lower 
concentrations of valine and leucine in late-onset FGR38, nor we could demonstrate differences in other essentials 
aminoacids in SGA fetuses as reported in other studies36,37,80. Favretto et al. reported up regulation of phenylala-
nine, tryptophan, and glutamate in FGR fetuses37, while Ivorra et al. reported significant differences cord blood 
concentrations of five aminoacids in FGR fetuses (proline, glutamine and alanine were reduced, while pheny-
lalanine and citrulline were increased)36. In previous studies, early-onset FGR showed significant decrease in 
glucose63,81, while no differences have been found in late-onset FGR63. It is known that glucose levels are inversely 
correlated to the clinical severity of FGR and the capability of transplacental glucose gradient, which might differ 
between the two phenotypes. Thus, these discrepancies suggest differences in case selection, platforms and proto-
cols used among studies assessing metabolites in placental dyfunction36,37.
Metabolic differences between small-for-gestational age and growth-restricted fetuses. FGR 
has two main clinical presentations, early-and late-onset disease. Early-onset FGR is highly associated with severe 
placental insufficiency and chronic fetal hypoxia82,83. In early-onset FGR, the typical scenario is a progressive 
deterioration of fetal well-being, accompanied with higher rates of preeclampsia and adverse perinatal outcomes, 
often requiring preterm delivery4. On the other hand, late-onset FGR represents 70–80% of FGR, has less signs of 
placental disease and the association with preeclampsia is minimal84. Despite a more benign nature as compared 
with early FGR, and that chronic hypoxia seems to be mild, the increase demands of oxygen and nutrients by 
vital organs such as brain and heart towards term increase the risk of acute fetal deterioration before labor, as 
suggested by the high contribution to late-pregnancy mortality, and a high association with intra- partum fetal 
distress and neonatal acidosis85. One of the aims was to evaluate whether late-onset SGA and FGR are associated 
with differential metabolomic patterns. Although there is a widely shared assumption that SGA are “constitution-
ally small”, but otherwise normal, fetuses, more recent studies reported that SGA display similar, albeit milder, 
neurodevelopmental and cardiovascular changes as those observed in FGR fetuses13,14,25,86,87. In line with this, 
the present study found that SGA and FGR fetuses had remarkably similar pattern of alterations in maternal and 
fetal lipid profiles, although there was a gradation of metabolic disruption according to the severity of the disease. 
These findings support that, at least a proportion of SGA fetuses represent a milder clinical form of true growth 
restriction not associated with Doppler changes or increased obstetrical risks. It could be hypothesized that SGA 
fetuses suffer undernutrition and its long-term consequences, but the respiratory function of the placenta is still 
Adequate for Gestational 
Age N = 28
Small for Gestational 
Age N = 25
Fetal Growth 
Restriction N = 27 p values







Isoleucine 0.23 (0.19–0.26) 0.2 (0.18–0.25) 0.23 (0.2–0.26) 0.17 0.96 0.56
Lactate 16.9 (13.2–21.4) 16.1 (13.5–23.6) 18.7 (12.2–25.2) 0.99 0.61 0.35
Leucine 0.35 (0.32–0.42) 0.35 (0.3–0.4) 0.36 (0.31–0.42) 0.53 0.98 0.52
Mannose 0.96 (0.79–1.1) 0.89 (0.78–0.96) 0.89 (0.8–1.03) 0.2 0.72 0.68
2-oxoisovaleric acid 0.1 (0.08–0.11) 0.1 (0.08–0.12) 0.11 (0.09–0.12) 0.65 0.14 0.07
Phenylalanine 1.46 (1.05–1.64) 1.20 (0.89–1.5) 1.26 (0.91–1.42) 0.75 0.13 0.23
Pyruvate 0.46 (0.44–0.49) 0.48 (0.46–0.53) 0.52 (0.44–0.56) 0.26 0.2 0.08
Tyrosine 0.71 (0.6–0.89) 0.6 (0.4–0.94) 0.84 (0.54–0.91) 0.27 0.99 0.55
Valine 1.12 (0.92–1.32) 1.1 (0.95–1.35) 1.18 (0.92–1.41) 0.99 0.74 0.4
Table 3. Metabolic profiling and targeted metabolomics in cord blood across the study groups. HDL: High-
density lipoprotein; IDL: Intermediate density lipoprotein; IQR: Interquartile range; LDL: Low-density 
lipoprotein; VLDL: Very low-density lipoprotein. Concentration, size and properties of the peaks are presented 
as median and interquartile range (IQR).
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largely preserved. Consequently, while the clinical distinction between “low risk” SGA and FGR is relevant for 
obstetrical management, fetal smallness represents a (potential) high-risk situation for long-term quality of life 
since metabolic adaptations occurs in utero regardless of its clinical prenatal presentation.
Strengths and limitations. The strengths of this study include the prospective design and the inclusion 
of a well-defined cohort including samples from mothers and fetuses of both, SGA and FGR cases with a rel-
atively large sample size, meaning that the possibility of selection bias was minimized. From a methodologi-
cal standpoint, the platforms used are highly reproducible and standardized. NMR and mass spectrometry are 
not mutually exclusive but rather complementary. They have advantages and disadvantages, and the method of 
choice depends on the aim of the study. One of the main advantages of NMR is its extraordinary reproducibility, 
which makes this technique a very good option for fingerprinting analysis, such as the study reported herein. 
Besides identification, we had the interest of quantify specific lipids, therefore we have used NMR spectroscopy 
since the peak area of a compound in the NMR spectrum is directly related to the concentration of specific 
nuclei, making quantification of compounds in a complex mixture very precise88,89. On the other hand, NMR is 
a non-destructive technique that allows samples to be recovered after analysis, which is not trivial considering 
the incalculable value of these samples. While basal contamination with macromolecules and lipids in the plasma 
are usually overlooked, herein, were discriminated and quantified and in addition, the resolution of spectral 
process described (buckets within 0.003 ppm) is significantly higher to that reported before (buckets within 0.05 
ppm)36–38. Moreover, the meticulous deconvolution process applied to each metabolite, is by far more rigorous, 
than the “blinded” quantification previously used36–38.
This is the first time that Liposcale is used in pregnancy. This test was originally developed to rapidly produce 
a lipoprotein profile of an individual’s plasma as part of cardiovascular disease risk work up90,91. The positive 
correlations describe between Liposcale and enzymatic colorimetric methods suggests that these variations are 
Figure 3. Heat map following metabolomic profiling on the annotated and significant (among the three 
groups) identified in plasma samples of mothers and neonates. A colored heat map of significant LMW 
metabolites and the Liposcale analysis along with their p-values, and percentage of fold change was obtained 
to visualize and characterize the differences between adequate for gestational age (AGA), all cases with a 
birthweight below the 10th centile (BW <10th) and separately small-for-gestational age (SGA) as well as fetal 
growth restriction (FGR) groups from maternal and umbilical cord blood. Fold change of significant differences 
(p < 0.05) for each metabolite are on a graded color scale from green (lower value) to black (no differences) to 
red (high values).
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biologically relevant. Yet, we acknowledge several limitations. First, our sample size may cover potential associa-
tions in other metabolites and hide interaction of confounders (clinical characteristics similar among populations 
but non-obvious confounders could have affected). Secondly, as we focused in late-onset FGR (by far, the most 
common clinical presentation), we might have missed the most extreme and severe cases occurring before 32 
weeks of gestation, in which fetal metabolic adaptations might be of uttermost relevance. Third, it is likely that 
our classification has overlapping between SGA and FGR, and for instance it is likely that constitutional small 
fetuses were included. Fourth, because of the design of the study, we only had few maternal samples of elective 
cesarean sections (maternal fasting conditions) and thus, non-fasting blood samples were collected. Typically, 
there is marginal effect of fasting on total cholesterol, HDL-C, and LDL-C, although triglycerides have a tendency 
to increase approximately 15% in non-fasting vs. fasting samples92–94. Fifth, although questionable, other more 
difficult to control confounding factors such as differences in the length of labor, time lapse difference between 
maternal and fetal sampling95 or seasonal variation of lipid profile96 might influence maternal lipid profile in the 
same form as fetal gender might influence the metabolomic profile of the fetuses included97. Future studies with 
a larger sample size might include these confounding factors into the analysis.
Conclusion
In summary, metabolic profiling combined with clinical phenotyping demonstrates the potential to enrich strati-
fied medicine research, revealing that mothers of small fetuses present substantial reductions in lipid metabolites, 
suggesting a failure in the maternal metabolic adaptation to pregnancy. While, both, SGA and growth-restricted 
fetuses have a substantial increase in lipids, indicating a similar metabolic response to undernutrition, there was 
a gradation of the metabolic disruption according to the severity of the phenotype.
Materials and Methods
Subjects and sample collection. This study is part of a larger prospective research program on FGR at 
the Department of Maternal-Fetal Medicine in Hospital Clinic Barcelona, involving maternal, fetal, and perinatal 
outcomes, as well as short- and long-term postnatal follow-up. A prospective cohort of singleton gestations with 
antenatal suspicion of fetal smallness and diagnosis established later than 32 weeks of gestation, were prospec-
tively followed; those who delivered neonates with a birthweight below the 10th centile at term (≥37 weeks of 
gestation) were included as cases (n = 52). According to our clinical protocol, small fetuses were subdivided: those 
with a birthweight <3rd centile and/or abnormal uterine artery Doppler and/or abnormal cerebroplacental ratio 
were termed fetal growth restriction (FGR), while those with a birthweight between the 3rd and the 9th centile and 
normal fetoplacental Doppler were considered small-for-gestational age (SGA) cases. A control group of 28 preg-
nancies with adequate-for-gestational ages (AGA) fetuses were selected among low-risk pregnancies attending 
third trimester routine pregnancy care and were included if they delivered term neonates with a normal birth-
weight (between 20th and 90th centile). Exclusion criteria included multiple gestations, spontaneous preterm labor 
or delivery, premature rupture of membranes, chromosomal abnormalities or major structural abnormalities. All 
the patients included in this study were delivered at term and did not receive steroids for fetal lung maturity. The 
Institutional Research and Ethics Committee approved the study protocol (review board 2014/7154), all parents 
gave their written informed consent and all experiments were performed in accordance with relevant guidelines 
and regulations.
Clinical and Ultrasound Data. Maternal, perinatal and neonatal data were prospectively recorded in 
all patients. Gestational age was calculated on the basis of fetal crown-rump length, measured at 11–13 weeks. 
Transabdominal ultrasound with Doppler evaluation was performed in both, cases and controls, at recruit-
ment, using 6-4-MHz probes (Siemens Sonoline Antares, Siemens Medical Systems, Malvern, PA, USA) and a 
Voluson 730 Expert Machine (GE Medical systems, Zipf, Austria). Estimated fetal weight (EFW) was calculated 
using the Hadlock formula98, and adjusted according to fetal gender and gestational age using local standards99. 
Feto-placental Doppler included: umbilical artery-pulsatility index (PI), mean uterine artery PI and middle cer-
ebral artery PI. The cerebroplacental ratio was calculated as middle cerebral artery PI/umbilical artery PI100, and 
defined as abnormal when <5th centile for gestational age100. The mean uterine arteries PI value was considered 
abnormal when >95th centile101. Cases of FGR were delivered electively between 37 and 38 weeks of gestation, 
while SGA cases were allowed to deliver up to 40 weeks of gestation5,6,11. Controls were allowed to have a sponta-
neous onset of labor but, if they reached 41 weeks of gestation, induction of labor was offered.
Biological samples collection and storage. Maternal blood samples were drawn 2–4 hours after delivery 
(non-fasting conditions but at least eight hours after their last meal and blood sampling). Umbilical vein cord 
blood samples were obtained from the clamped umbilical cord immediately after delivery of the fetus. All blood 
samples were collected in EDTA-treated tubes and processed within one hour. Plasma was separated by centrifu-
gation at 3000 rpm for 10 minutes at 4 °C, and stored at −80 °C until further use.
NMR data acquisition. Plasma samples were thawed overnight and prepared for nuclear magnetic res-
onance (NMR) analyses according to the Bruker-specific metabolomics protocol102. Aliquots of each sam-
ple (300 μl) were mixed with 300 μl of sodium phosphate buffer for immediate analysis. High-resolution 
1H-NMR spectroscopy data were acquired on a Bruker 600 MHz Spectrometer (Bruker Biospin, Rheinstetten, 
Germany) equipped with an Avance III console and a TCI CryoProbe Prodigy: 1D Nuclear Overhauser Effect 
SpectroscopY (NOESY), Carr-Purcell-Meiboom-Gill (CPMG), and 2D j-resolved spectroscopy (JRES), all with 
pre-saturation to suppress the residual water peak, to characterize small molecules such as amino acids and sug-
ars; and 1D Diffusion (Diff, TR/TE, b values, NS, ACQ), to detect larger molecules such as lipoproteins, glyco-
proteins and choline compounds103,104. All the sequences were run at 37 °C in quantitative conditions (systematic 
pre-calibration of radio frequency pulses and sample temperature, and same receiver gain adjustment). CPMG 
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and Diff data were preprocessed at the NMR console (TopSpin 3.2, Bruker Biospin, Rheinstetten, Germany) for 
basic corrections, such as phase correction and exponential line broadening (0.5 Hz for CPMG; 1.0 Hz for Diff).
NMR fingerprinting analysis. For the metabolic fingerprinting analysis, spectral vectors were generated 
from the CPMG and Diff data by binning (0.003 ppm), alignment (alanine, 1,475 ppm) and region suppression 
(to minimize the influence of water and EDTA signals, specific to the CPMG data). This was carried out with 
MestReNova v11.0.3 (Mestrelab Research S.L., Santiago de Compostela, Spain). These spectral vectors were used 
for automatic spectroscopic data categorization by clustering analysis (ASCLAN), a supervised method to quickly 
assess discriminatory spectral regions (and indirectly metabolites) in the study groups105. The Diff NMR data 
was further used for lipoprotein profiling, based on the Liposcale test90,91. This test provides information about 
the size, lipid concentration (cholesterol and triglycerides) and number of particles for the main classes of lipo-
proteins [very-low density lipoprotein (VLDL), low-density lipoprotein (LDL), intermediate-density lipoprotein 
(IDL) and high-density lipoprotein (HDL)], as well as the concentration of particles in their subclasses (large, 
median, small)90,91. The Diff NMR data was also used to quantify choline compounds (3.3–3.18 ppm) and glyco-
proteins (2.15-1.9 ppm), based on peak deconvolutions. Details of the method for the Liposcale for lipoprotein 
characterization and phosphatidylcholines compounds and glycoprotein peak deconvolution are explained in 
the supplemental material. Finally, CPMG data was used for the profiling of 20 metabolites, based on a new, fully 
automated version of the software package Dolphin106,107. Signal annotation was based on templates prepared in 
previous studies with the help of available databases108 and bibliography109–111. Validation of metabolite identifi-
cation was assisted by STOCSY112 and JRES data.
Statistical analysis. Categorical data are presented as n (%) and continuous data as mean (±SD) or median 
[interquartile range (IQR)] according to their distribution. To assess the categorical variables, proportions were 
compared with Fisher’s exact test or the chi-square test. Distributions of continuous variables were examined for 
normality using the Kolmogorov-Smirnov test. When there was normality of continuous variables, the one-way 
ANOVA test and unpaired t-tests were used to compare differences. Otherwise, the Kruskal-Wallis one-way 
analysis of variance and Mann-Whitney U-test were used. Correlation between selected metabolites concentra-
tions by 1H-NMR and enzymatic colorimetric methods were assessed with Pearson coefficients (or Spearman 
for non-normal distributions). To initially evaluate the ability of metabolites in distinguishing cases from con-
trols, orthogonal partial least square discriminant analysis (OPLS-DA) was performed based on multivariate, 
supervised, discriminant analysis of spectral vectors – Automatic Spectroscopic data Categorization by cLustering 
ANalysis (ASCLAN)105. Finally, the Jonckheere–Terpstra test was also used to test if the concentration of metabo-
lites followed a ordered alternative hypothesis across severity groups (controls-SGA-FGR)113,114. Statistical analy-
sis was performed using STATA 14 (Stata Corp LP, 2015, College Station, Texas) and MATLAB (MathWorks Inc, 
US). A p-value < 0.05 was considered to be statistically significant.
Data Availability Statement
Clinical information of the patients included, spectrum data and associated protocols are promptly available to 
readers without undue qualifications in material transfer agreements.
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